Michael Makris
#145,216
Most Influential Person Now
Researcher
Michael Makris's AcademicInfluence.com Rankings
Michael Makriscomputer-science Degrees
Computer Science
#7226
World Rank
#7610
Historical Rank
Machine Learning
#2605
World Rank
#2640
Historical Rank
Artificial Intelligence
#2896
World Rank
#2941
Historical Rank
Database
#4291
World Rank
#4463
Historical Rank
Download Badge
Computer Science
Michael Makris's Degrees
- Masters Computer Science Stanford University
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Michael Makris Influential?
(Suggest an Edit or Addition)Michael Makris's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Increased fetal loss in women with heritable thrombophilia (1996) (670)
- Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. (2007) (618)
- Guidelines on oral anticoagulation with warfarin – fourth edition (2011) (568)
- Clinical guidelines for testing for heritable thrombophilia (2010) (443)
- Recurrent miscarriage: aetiology, management and prognosis. (2002) (429)
- Emergency Oral Anticoagulant Reversal: The Relative Efficacy of Infusions of Fresh Frozen Plasma and Clotting Factor Concentrate on Correction of the Coagulopathy (1997) (407)
- Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. (2021) (327)
- COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation (2020) (285)
- Hepatitis C antibody and chronic liver disease in haemophilia (1990) (245)
- Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders (2008) (240)
- Demonstration of viraemia patterns in haemophiliacs treated with hepatitis-C-virus-contaminated factor VIII concentrates (1990) (216)
- Thrombin generation testing in routine clinical practice: are we there yet? (2008) (213)
- A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over‐anticoagulation with warfarin (2001) (206)
- Enhanced thrombin generation in patients with cirrhosis‐induced coagulopathy (2010) (198)
- Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia (1997) (198)
- Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) (2005) (197)
- Guideline on the management of bleeding in patients on antithrombotic agents (2013) (195)
- The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals (2010) (185)
- The natural history of chronic hepatitis C in haemophiliacs (1996) (173)
- Measurement of non‐Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology (2014) (152)
- Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors (2006) (152)
- A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. (2008) (152)
- Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males (2019) (151)
- Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin α2β1 (2003) (142)
- Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. (2000) (142)
- Guidelines on the investigation and management of venous thrombosis at unusual sites (2012) (142)
- Guideline on aspects of cancer‐related venous thrombosis (2015) (137)
- Venous Thrombosis Following the Use of Intermediate Purity FVIII Concentrate to Treat Patients with Von Willebrand’s Disease (2002) (114)
- The management of coumarin‐induced over‐anticoagulation (2001) (111)
- Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects (2016) (109)
- Inhibitor development in haemophilia according to concentrate (2015) (107)
- Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects. (2013) (107)
- Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia (2005) (104)
- Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) (2013) (101)
- Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. (2012) (98)
- Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters (2008) (98)
- Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient (2010) (96)
- Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic (2020) (96)
- Evaluation of laboratory assays for anti‐platelet factor 4 antibodies after ChAdOx1 nCOV‐19 vaccination (2021) (95)
- Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. (1998) (95)
- Vaccine-induced immune thrombotic thrombocytopenia (2021) (94)
- Familial thrombophilia and lifetime risk of venous thrombosis (2004) (93)
- Whole genome sequencing of a sporadic primary immunodeficiency cohort (2018) (92)
- Vaccine‐induced Immune Thrombocytopenia and Thrombosis (VITT) (2021) (91)
- Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. (2007) (90)
- A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. (1991) (90)
- Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease. (1995) (90)
- Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. (2003) (89)
- Practical Hemostasis and Thrombosis (2008) (89)
- Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies (2012) (89)
- Hereditary thrombophilia and fetal loss: a prospective follow‐up study (2004) (87)
- Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro (2008) (86)
- Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. (1993) (80)
- Protamine reversal of low molecular weight heparin: clinically effective? (2011) (79)
- Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. (2009) (76)
- Prophylaxis in haemophilia should be life-long. (2012) (73)
- EUHASS: The European Haemophilia Safety Surveillance system. (2011) (73)
- Increased prevalence of hypertension in haemophilia patients (2012) (72)
- Routine preoperative coagulation tests: an outdated practice? (2011) (68)
- Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources (2021) (67)
- Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee (2018) (66)
- Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients (2012) (66)
- Familial thrombophilia: genetic risk factors and management (1997) (65)
- The phenotypic and genetic assessment of antithrombin deficiency (2011) (64)
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression (2013) (62)
- The management of coumarin-induced over-anticoagulation Annotation. (2001) (62)
- The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies (2011) (61)
- The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C (1994) (60)
- Gastrointestinal bleeding in von Willebrand disease. (2006) (60)
- Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? (2011) (57)
- The impact of HIV on mortality rates in the complete UK haemophilia population (2004) (57)
- Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill (2007) (56)
- Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A. (2009) (56)
- Thrombosis in Inherited Fibrinogen Disorders (2017) (52)
- Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A (2013) (52)
- Hyperhomocysteinemia and thrombosis. (2000) (51)
- Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. (2014) (50)
- Detection by PCR of hepatitis C virus in factor VIII concentrates (1990) (50)
- A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis (1999) (49)
- Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. (2015) (48)
- NHF‐McMaster Guideline on Care Models for Haemophilia Management (2016) (48)
- Poor reversal of low molecular weight heparin by protamine (2000) (47)
- Phenotypic approaches to gene mapping in platelet function disorders (2010) (47)
- Clotting factor concentrate switching and inhibitor development in hemophilia A. (2012) (47)
- Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation (2008) (47)
- How to discuss gene therapy for haemophilia? A patient and physician perspective (2019) (46)
- Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder (2004) (46)
- Management of peri‐operative anti‐thrombotic therapy (2015) (44)
- Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study (2007) (42)
- A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. (2013) (42)
- Hyperhomocysteinemia in women with advanced breast cancer (2007) (42)
- The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease (2015) (42)
- Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations (2018) (41)
- SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria? (2004) (41)
- FXI concentrate use and risk of thrombosis (2014) (41)
- The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH (2018) (41)
- Emicizumab and thrombosis: The story so far (2019) (40)
- The World Federation of Hemophilia Annual Global Survey 1999‐2018 (2020) (40)
- Non-O blood group: an important genetic risk factor for venous thromboembolism. (2013) (39)
- Optimisation of the prothrombin complex concentrate dose for warfarin reversal. (2005) (39)
- Activation of Coagulation in Diabetes Mellitus in Relation to the Presence of Vascular Complications (1991) (39)
- Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network (2015) (38)
- Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency (1994) (37)
- Parvovirus transmission by blood products – a cause for concern? (2012) (37)
- Optimizing warfarin reversal – an ex vivo study (2009) (36)
- Characterisation of Type 2N von Willebrand Disease Using Phenotypic and Molecular Techniques (1996) (36)
- Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report (2019) (35)
- Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V leiden. (1996) (35)
- In vivo coagulation activation following infusion of highly purified factor XI concentrate (1997) (34)
- Management of muscle haematomas in patients with severe haemophilia in an evidence‐poor world (2012) (34)
- Thrombophilia: grading the risk. (2009) (34)
- Hyperhomocysteinemia and venous thrombosis. (2007) (33)
- History of non‐fatal cardiovascular disease in a cohort of Dutch and British patients with haemophilia (2012) (33)
- Third Åland islands conference on von Willebrand disease, 26–28 September 2012: meeting report (2013) (33)
- Inherited Thrombophilia and Pregnancy Complications: Should We Test? (2018) (33)
- Is recombinant FVIIa the magic bullet in the treatment of major bleeding? (2005) (33)
- Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin (2009) (32)
- The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents (2009) (32)
- Is VIII worse than IX? (2009) (32)
- Major Structural Defects in the Antithrombin Gene in Four Families with Type I Antithrombin Deficiency (2000) (32)
- The risk of variant Creutzfeldt‐Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products (2011) (32)
- Immunization of patients with bleeding disorders (2003) (32)
- Minimal factor XIII activity level to prevent major spontaneous bleeds (2017) (31)
- Normal prothrombin time in the presence of therapeutic levels of rivaroxaban (2013) (30)
- Cognitive appraisals and psychological distress following venous thromboembolic disease: an application of the theory of cognitive adaptation. (2006) (30)
- Real‐life experience in switching to new extended half‐life products at European haemophilia centres (2019) (30)
- Pregnancy outcome in women with factor V Leiden and recurrent miscarriage (2009) (28)
- New findings on inhibitor development: from registries to clinical studies (2017) (28)
- The management of von Willebrand's disease-associated gastrointestinal angiodysplasia (2001) (28)
- Concentrate‐related inhibitor risk: is a difference always real? (2011) (28)
- Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature (2006) (27)
- First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties (2017) (26)
- The European standards of Haemophilia Centres. (2014) (26)
- Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia (2001) (26)
- Evaluation of a semi‐automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers (2018) (26)
- Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate‐related myocardial infarction in patients with haemophilia and inhibitors (2000) (26)
- De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures (2018) (26)
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors. (2004) (25)
- Kilt Syndrome? (2002) (25)
- Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy. (2013) (25)
- p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it (2011) (24)
- Chronic hepatitis in haemophilia. (1993) (24)
- Warfarin Induced Skin Necrosis Associated with Activated Protein C Resistance (1996) (23)
- Care models in the management of haemophilia: a systematic review (2016) (23)
- Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis (2012) (23)
- The reversal of anticoagulation in clinical practice . (2018) (22)
- Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity (2014) (21)
- Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia. (2001) (21)
- A Novel Mutation in Intron K of the PROS1 Gene Causes Aberrant RNA Splicing and Is a Common Cause of Protein S Deficiency in a UK Thrombophilia Cohort (1998) (21)
- Risk reduction strategies for variant Creutzfeldt–Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders (2010) (21)
- Haemophilia and ageing (2018) (20)
- The successful use of protein C concentrate during pregnancy in a patient with type 1 protein C deficiency, previous thrombosis and recurrent fetal loss (1997) (20)
- A comprehensive targeted next‐generation sequencing panel for genetic diagnosis of patients with suspected inherited thrombocytopenia (2018) (20)
- Influence of the −675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden (2000) (20)
- Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits (2003) (20)
- Textbook of Haemophilia (2006) (20)
- Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. (2007) (20)
- Factor V Leiden in Greek thrombophilia patients: relationship with activated protein C resistance test and levels of thrombin‐antithrombin complex and prothrombin fragment 1+2 (1997) (19)
- Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies (2012) (19)
- The European Haemophilia Network (EUHANET). (2014) (19)
- Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis (2022) (19)
- Factor VIII assay variability in postinfusion samples containing full length and B‐domain deleted FVIII (2016) (18)
- Management of excessive anticoagulation or bleeding. (2003) (18)
- How I treat inhibitors in haemophilia (2012) (18)
- The coagulation laboratory monitoring of Afstyla single‐chain FVIII concentrate (2017) (18)
- Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies (2020) (18)
- Prophylaxis in von Willebrand Disease: Coming of Age? (2016) (18)
- Anti‐PF4 testing for vaccine‐induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: Results from a UK National External Quality Assessment Scheme exercise April 2021 (2021) (17)
- Practical Hemostasis and Thrombosis: Key/Practical Hemostasis and Thrombosis (2010) (17)
- Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G20210A genotypes from blood samples without the need for DNA extraction (2003) (17)
- Lifelong penicillin unproved in trials.. (1994) (17)
- Inhibitor development in non-severe haemophilia across Europe (2015) (17)
- Malignant disease in the haemophilic population: moving towards a management consensus? (2012) (17)
- Dealing with the uncertain risk of variant Creutzfeldt‐Jakob disease transmission by coagulation replacement products (2012) (16)
- Peripheral mononuclear cells of haemophiliacs with chronic liver disease are infected with replicating hepatitis C virus (1994) (16)
- Enhancing haemophilia care through registries (2014) (16)
- Clinical assessment of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A (2011) (16)
- Identification and characterization of a novel P 2 Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1 VWD study (2009) (16)
- Choosing and using non‐steroidal anti‐inflammatory drugs in haemophilia (2016) (16)
- Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC (2021) (16)
- Factor VIII products and inhibitors in severe hemophilia A. (2013) (16)
- The World Federation of Hemophilia guideline on management of haemophilia (2013) (16)
- Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin (2018) (16)
- Assaying FVIII activity: one method is not enough, and never was (2014) (15)
- Clotting and chromogenic factor VIII assay variability in post‐infusion and spiked samples containing full‐length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc) (2019) (15)
- A rapid, automated VWF ristocetin cofactor activity assay improves reliability in the diagnosis of Von Willebrand disease. (2011) (14)
- Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity—a rebuttal (2005) (14)
- Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients (2018) (14)
- FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies (2016) (14)
- Viral hepatitis in haemophilia: historical perspective and current management (2021) (14)
- Src family kinases are essential for primary aggregation by Gi‐coupled receptors (2010) (14)
- Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. (2022) (14)
- Altitude and Coagulation Activation: Does Going High Provoke Thrombosis? (2008) (13)
- Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. (2010) (13)
- Summary report of the First International Conference on inhibitors in haemophilia A. (2017) (13)
- Establishment of the 1st International Genetic Reference Panel for Factor V Leiden, human gDNA (2006) (13)
- UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011 (2011) (13)
- Increased soluble IL‐2 receptor levels in HCV‐infected haemophiliacs: a possible indicator of liver disease severity (1994) (13)
- Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen (2014) (13)
- THE USE OF ORAL VITAMIN K FOR REVERSAL OF OVER‐WARFARINIZATION (2002) (12)
- The 2021 von Willebrand disease guidelines: Clarity and controversy (2022) (12)
- Potential thrombogenicity of heat‐treated prothrombin complex concentrates in Haemophilia B (1991) (12)
- Measurement of extended half‐life recombinant factor IX products in clinical practice (2018) (11)
- Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more (2017) (11)
- Pharmacokinetics of Optivate®, a high‐purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A (2011) (11)
- A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use (2012) (11)
- Management of comorbidities in haemophilia (2020) (11)
- Wobble ( T 85 M / K ) : Archetypal Conformational Diseases With In Vivo Latent-Transition , Thrombosis , and Heparin Activation (1998) (11)
- An evaluation of screening tests for defects in the protein C pathway: commercial kits lack sensitivity and specificity (2002) (11)
- Evaluation of a new venom‐based clotting assay of protein C (2008) (11)
- An Interpretative Phenomenological Analysis of Adaptation to Recurrent Venous Thrombosis and Heritable Thrombophilia (2008) (11)
- Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update (2021) (11)
- Management of bleeding and procedures in patients on antiplatelet therapy. (2020) (11)
- Interferon alfa for chronic hepatitis C in haemophiliacs. (1993) (10)
- The investigation of a prolonged APTT with specific clotting factor assays is unnecessary if an APTT with Actin FS is normal (2011) (10)
- Mesenteric infarction due to combined protein C deficiency and prothrombin 20210 defects (1999) (10)
- Axillary vein thrombosis in a healthy donor following platelet apheresis (2002) (10)
- A golden age for Haemophilia treatment? (2018) (10)
- Bone marrow biopsy related haemorrhage and low molecular weight heparin (2003) (10)
- Inhibitor development in haemophilia (2017) (10)
- A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment (2017) (10)
- Systematic review of the management of patients with haemophilia A and inhibitors (2004) (10)
- Minimal dataset for post‐registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH (2017) (10)
- Evolution of Haemophilia Care in Europe: 10 years of the principles of care (2020) (10)
- Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. (2009) (10)
- Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series (2017) (9)
- Prevention of hepatitis C virus infection in haemophiliacs (1990) (9)
- Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO‐RBDD project laboratories (2017) (9)
- Prothrombin complex concentrate for non‐vitamin K oral anticoagulant reversal: good enough for now? (2014) (9)
- Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population? (2018) (9)
- Management of COVID‐19‐associated coagulopathy in persons with haemophilia (2020) (9)
- Safety surveillance in haemophilia and allied disorders (2016) (9)
- Need for second-generation anti-HCV testing in haemophilia (1992) (8)
- Biovigilance and pharmacovigilance for haemophilia (2010) (8)
- Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? (2021) (8)
- Congenital macrothrombocytopenia is a heterogeneous disorder in India (2016) (8)
- Between‐batch variation of calibrator activity can significantly influence fluorogenic measurement of thrombin generation (2006) (8)
- Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders (2021) (8)
- Platelet-Activating Anti-Platelet Factor 4/Polyanion Antibodies without Preceding Heparin Therapy: A Transient Autoimmune Disorder Resembling Heparin-Induced Thrombocytopenia (“Spontaneous HIT”). (2006) (7)
- Adoption of emicizumab (Hemlibra®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey (2021) (7)
- Prothrombin complex concentrate-related thrombotic risk following anticoagulation reversal (2012) (7)
- Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q) (2019) (7)
- Detection of Factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO‐RBDD project laboratories (2017) (7)
- Hepatitis C in haemophilia: time for treatment for all (2017) (7)
- Hyperhomocysteinemia is a risk factor for venous and arterial thrombosis. (1998) (7)
- Vaccination induced neutropenia (2013) (7)
- Use of the Polymerase Chain Reaction to Detect Viral Contamination of Clotting Factor Concentrates (1994) (7)
- Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study (2021) (6)
- Reply to escobar (2002) (6)
- The effect of DOAC‐Stop® on several oral and parenteral anticoagulants (2021) (6)
- Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery (2011) (6)
- Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC (2022) (6)
- Recombinant factor VIIa for unlicensed indications – a definite No or a cautious Maybe in selected patients? (2010) (6)
- Vaccine‐induced immune thrombotic thrombocytopenia (VITT) ‐ update on diagnosis and management considering different resources: Response to Comment from Yamada et al (2022) (6)
- Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH (2016) (6)
- Protein C deficiency screening using a thrombin generation assay – An upgrade (2007) (6)
- Null Alleles Are not a Common Cause of Type 1 von Willebrand Disease in the British Population (1999) (6)
- Paracetamol/acetaminophen usage in haemophilia: more caution needed? (2008) (5)
- Evaluation of a global screening assay for the investigation of the protein C anticoagulant pathway. (2000) (5)
- Hemophilia gene therapy is effective and safe. (2018) (5)
- Failure of recombinant FVIIa as treatment for abdominal bleeding in acquired hemophilia (2001) (5)
- Laboratory Tests of Hemostasis (2010) (5)
- Update to UKHCDO guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease (2013) (5)
- Clinical outcomes and the impact of prior oral anticoagulant use in patients with coronavirus disease 2019 admitted to hospitals in the UK — a multicentre observational study (2021) (5)
- Factor V Leiden: to test or not to test, that is the debate. (2012) (4)
- Gene therapy 1·0 in haemophilia: effective and safe, but with many uncertainties. (2020) (4)
- SIPPET trial: the answers (2017) (4)
- Longer FVIII: the 4th generation. (2012) (4)
- Noonan syndrome associated with bleeding disorders (2010) (4)
- Bias due to publication of positive results with treatments for thrombotic thrombocytopenic purpura (1991) (4)
- A biopsy-controlled trial of interferon alfa-2b in chronic NANB hepatitis in hemophiliacs (1990) (4)
- UKHCDO Acquired Haemophilia Study: A Complete National Cohort. (2005) (4)
- Caution in Using the Activated Partial Thromboplastin Time to Monitor Argatroban in COVID-19 and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) (2021) (4)
- Staying updated on COVID‐19: Social media to amplify science in thrombosis and hemostasis (2020) (4)
- Disruptive technology and hemophilia care: The multiple impacts of emicizumab (2021) (4)
- A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. (2018) (4)
- The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. (2014) (4)
- Anti‐PF4 testing for vaccine‐induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide (2022) (4)
- Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS) (2019) (3)
- Pre-operative PCC for non-bleeding patients on warfarin. (2016) (3)
- The EHA Research Roadmap: Platelet Disorders (2021) (3)
- Reply to Comment on: Inherited Thrombophilia and Pregnancy Complications: Should We Test? (2019) (3)
- Safety of antithrombin III concentrate [letter; comment] (1990) (3)
- Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors (2020) (3)
- Hemophilia A treatment: disruptive technology ahead. (2016) (3)
- Safety of antithrombin III concentrate. (1990) (3)
- Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia (2020) (3)
- Haemophilia of the third age (2018) (3)
- Incidence of adult primary immune thrombocytopenia in England—An update (2022) (3)
- LIVER-TRANSPLANTATION IN HEMOPHILIA (1991) (3)
- Von Willebrand factor activity assay errors (2016) (3)
- A Novel Protac®-Modified Thrombin Generation Assay To Identify Individuals at Higher Thrombotic Risk. (2006) (3)
- Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow-up Study of the B-Amaze Program (2021) (3)
- Severe Wound Healing Impairment in a Patient with Dysfibrinogenaemia (2018) (3)
- Reversal of coumarin-induced over-anticoagulation. Authors' reply (2002) (3)
- Illustrated State‐of‐the‐Art Capsules of the ISTH 2020 Congress (2021) (2)
- Interferon-alpha treatment and formation of factor VIII antibodies. (1997) (2)
- Is fresh frozen plasma as good as prothrombin complex concentrate for vitamin K antagonist reversal in acute intracerebral hemorrhage? (2016) (2)
- Why is it so difficult to show that prothrombin complex concentrates are superior to fresh-frozen plasma for warfarin reversal? (2017) (2)
- Plagiarism and Haemophilia (2012) (2)
- Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company (2020) (2)
- Monthly haemoptysis in a woman with platelet storage pool disease. (2000) (2)
- Hepatitis and Hemophilia (2010) (2)
- ‘Haemophilia Guidelines for All’: A new ambition of the World Federation of Haemophilia (WFH) (2020) (2)
- Liver transplantation for factor XI deficiency: cure before diagnosis (2008) (2)
- The cardiac complications of COVID-19: many publications, multiple uncertainties (2020) (2)
- Three or four factor prothrombin complex concentrate for emergency anticoagulation reversal? The true question is: what are we looking for? (2011) (2)
- Interferon- Treatment and Formation of Factor VIII Antibodies (1997) (2)
- von Willebrand disease and extra‐intestinal angiodysplasia (2017) (2)
- The common haemochromatosis mutation does not increase the risk of thrombosis in patients with factor V Leiden (1999) (2)
- Alternative models of delivery of anticoagulant services. (1999) (2)
- Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020) (2)
- Erratum: Inherited Thrombophilia and Pregnancy Complications: Should We Test? (2019) (2)
- Determinants of inhibitor development in previously treated hemophilia A patients (2015) (1)
- Reversal of Anticoagulation as Assessed by Thrombin Generation Measurement. (2006) (1)
- LATE-BREAKING AND COVID-19 ORAL COMMUNICATION SESSION ABSTRACTS (2020) (1)
- Cardiovascular disease in hereditary haemophilia: The challenges of longevity (2022) (1)
- Air flight-related thrombosis: reality or hype? (2002) (1)
- The current state of adverse event reporting in hemophilia (2017) (1)
- The Management of the Haemophilic Arthropathy (2017) (1)
- MCMDM-1VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P2Y (2012) (1)
- Is the continued use of UK plasma sourced cryoprecipitate justified? (2015) (1)
- Publishing in Haemophilia (2019) (1)
- Transient inherited antithrombin deficiency: a real phenomenon? (2016) (1)
- Quality control of point of care INR devices is essential (2016) (1)
- More on: enhanced thrombin generation in patients with cirrhosis‐induced coagulopathy (2011) (1)
- Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort (2020) (1)
- Comparative analysis of marketed factor VIII products: comment (2019) (1)
- Twitter and Haemophilia (2020) (1)
- Second-dose VITT: rare but real (2022) (1)
- Sorting nexin 24 is required for α-granule biogenesis and cargo delivery in megakaryocytes (2022) (1)
- Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. (2020) (1)
- Cardiovascular disease history and risk factors in hemophilia patients [Abstract] (2012) (1)
- Whole exome sequencing in patients with inherited thrombocytopenia and excessive bleeding is an efficient way to identify genetic variants in known and novel genes (2015) (1)
- Retinal vein occlusion, the contraceptive pill and the prothrombin 20210A allele (1999) (1)
- Making treatment decisions in hemophilia based on available safety data (2021) (1)
- Reversal of coumarin-induced over-anticoagulation [5] (multiple letters) (2002) (1)
- Guidelines on the investigation and management of thrombosis at unusual sites (2012) (1)
- Liver biopsy in haemophilia. (1997) (1)
- C0327: Pregnancy May Falsely Reduce Antithrombin Antigen Levels in Latex-Based Assays (2014) (1)
- Comprar Practical Hemostasis And Thrombosis 3rd Ed. | Nigel Key | 9781118344712 | Wiley (2017) (1)
- Increased QRISK2 cardiovascular disease risk score in haemophilia patients (2011) (1)
- by UK Haemophilia Centre Doctors' Organisation Acquired haemophilia A in the UK: a two year national surveillance study (2013) (0)
- Characterization of a new therapeutic recombinant human anti-thrombin concentrate (2003) (0)
- C0339 An automated antithrombin antigen assay on instrumentation laboratory ACL top analyser (2012) (0)
- Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors: a systematic literature review. (2019) (0)
- Anticoagulation control with the point-of-care INR: A retrospective pre-/post-analysis. (2020) (0)
- Appendix 1: Reference Ranges (2010) (0)
- Identification of new platelet phenotypes through phenotyping and targetted sequencing (2011) (0)
- Abstract (2003) (0)
- Emicizumab is a recombinant, humanised bispecific monoclonal antibody that binds factor IXa and factor X. Although emicizumab mimics factor VIII, in that it enhances factor IXa- mediated factor X activation, its mechanism of action (2020) (0)
- Viral Hepatitis and Hemophilia (2014) (0)
- C0430 Is the presence of the mutation of FXIII a key of epigenetic impact in the expression of thrombophilic predisposition (2012) (0)
- agonist panel disorders including recommendation and validation of a streamlined Evaluation of participants with suspected heritable platelet function (2012) (0)
- Publisher Correction: Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (2018) (0)
- Meeting programme BSHT & UKHCDO Joint Meeting, October 2008 (2008) (0)
- Emicizumab for non-severe haemophilia A. (2023) (0)
- Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis (2011) (0)
- Both one-stage and chromogenic factor VIII assays are required for the diagnosis of mild hemophilia A. (2023) (0)
- proplatelet formation causing thrombocytopenia Sphingolipid dysregulation due to lack of functional KDSR impairs Version 3 HAEMATOL / 2018 / 204784 (2019) (0)
- Skin necrosis and coagulation factor abnormalities (2017) (0)
- Inherited Platelet Defects (2018) (0)
- Management of COVID-19 associated Coagulopathy in Persons with Haemophilia Interim Guidance on behalf of the Coagulation Products Safety, Supply and Access (CPSSA) Committee of the World Federation of Hemophilia (2020) (0)
- How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry (2021) (0)
- Does HIV infection accelerate malignant transformation of pre‐malignant states? (1992) (0)
- MCMDM-1 VWD study diagnosed with type 1 von Willebrand disease in the European variant in a patient 12 Identification and characterization of a novel P 2 Y (2009) (0)
- Identification of novel FLI1 mutations in two families with a platelet secretion defect (2013) (0)
- CARS STUDY OF LIQUID PARA-HYDROGEN AT DIFFERENT TEMPERATURES (2009) (0)
- Recent onset of bleeding and gross coagulopathy (2001) (0)
- Recent onset of bleeding and gross coagulopathy (2001) (0)
- Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data (2018) (0)
- Lack of association between polymorphisms in the interleukin-1 gene cluster and familial thrombophilia. (2012) (0)
- Prion and Prion-like Diseases in Humans (2013) (0)
- The natural history of hepatitis C in patients with bleeding disorders (2006) (0)
- Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients (2010) (0)
- Prothrombin Complex Concentrate for Warfarin Reversal: A Single Dose Is Effective for All INRs >4.5. (2008) (0)
- Hemophilia A and B (2010) (0)
- Unconventional diagnosis of Normandy‐type von Willebrand's disease in a blood donor (2004) (0)
- A new era for the Haemophilia journal (2013) (0)
- Response to antiviral therapy in patients with congenital bleeding disorders infected with hepatitis C (2006) (0)
- Appendices: Useful Websites (2007) (0)
- Uncertain times for research on hemophilia and allied disorders (2006) (0)
- P9 The molecular basis of antithrombin deficiency: a survey of twelve kindred (1996) (0)
- Enhanced surveillance of individuals identified as at increased risk of CJD in the UK thorugh iatrogenic exposure: An update (2013) (0)
- C0340 An automated progressive assay of antithrombin (2012) (0)
- Lack of correlation between microvessel density & pericyte coverage index with breast cancer biposies & functional dynamic contrast-enhanced MRI-derived vascular parameters (2005) (0)
- Thrombin Generation Is Normal in Most Patients with Cirrhosis despite a Prolonged INR. (2008) (0)
- Haemophilia 2012 (2012) (0)
- Table of Contents (2016) (0)
- Managing prostatic illness in persons with haemophilia (2022) (0)
- UK EHL OUTCOMES REGISTRY: REASON FOR SWITCHING TO EXTENDED HALF-LIFE PRODUCT (2020) (0)
- Haemophilia 2011 (2011) (0)
- Assessment of antithrombin deficiency in the real world (2011) (0)
- Using a registry to monitor inhibitor development in haemophilia: first results of EUHASS (2010) (0)
- Haemophilia 2010 (2010) (0)
- Chapter 5. Hemophilia A and B (2007) (0)
- Profile of mutations in a UK hemophilia A patient population (2003) (0)
- Thrombosis in congenital a-, dys- and hypofibrinogenemia (2017) (0)
- Haemophilia Centre Certification Systems: optional or optimal choice for healthcare systems? (2014) (0)
- Appendices: Normal Ranges (2007) (0)
- INTERFERON-ALPHA TREATMENT AND FORMATION OF FACTOR VIII ANTIBODIES. AUTHORS' REPLY (1997) (0)
- Venous thromboembolism: deep vein thrombosis and pulmonary embolism (2016) (0)
- Prospective Evaluation of Bleeding Incidence in Fibrinogen Deficiency (PRO-RBDD Study) (2016) (0)
- disorders and hepatitis C: an international, multicenter cohort-study Progression to end-stage liver disease in patients with inherited bleeding (2013) (0)
- Autoimmune disease and COVID-19: a multicentre observational study in the United Kingdom (2022) (0)
- Raised plasma homocysteine levels in women with metastatic breast cancer (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Makris?
Michael Makris is affiliated with the following schools:
